• We are sorry, but NCBI web applications do not support your browser and may not function properly. More information
Logo of brjclinpharmLink to Publisher's site
Br J Clin Pharmacol. Apr 1986; 21(4): 401–408.
PMCID: PMC1400935

Racial differences in drug responses--a comparative study of trimazosin and alpha 1-adrenoceptor responses in normotensive Caucasians and West Africans.

Abstract

The possible racial differences in alpha 1-adrenoceptor responsiveness and the blood pressure and heart rate responses following alpha 1-adrenoceptor antagonism with trimazosin have been investigated in matched groups of six Caucasians and six Nigerians. There were no significant differences between the racial groups in the blood pressure and heart rate responses to oral (200 mg) and intravenous (100 mg) trimazosin. alpha 1-adrenoceptor responsiveness was similar in both groups after placebo and following both active treatments. There were only minor pharmacokinetic differences with the Caucasians having a larger volume of distribution, and a longer terminal elimination half-life for the metabolite, 1-hydroxy-trimazosin. These results suggest a similarity in peripheral vascular alpha 1-adrenoceptor mechanisms and show no major significant racial differences in the pharmacokinetics and pharmacodynamics of trimazosin.

Full text

Full text is available as a scanned copy of the original print version. Get a printable copy (PDF file) of the complete article (1001K), or click on a page image below to browse page by page. Links to PubMed are also available for Selected References.

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Alvares AP, Anderson KE, Conney AH, Kappas A. Interactions between nutritional factors and drug biotransformations in man. Proc Natl Acad Sci U S A. 1976 Jul;73(7):2501–2504. [PMC free article] [PubMed]
  • Anderson KE, Conney AH, Kappas A. Nutrition and oxidative drug metabolism in man: relative influence of dietary lipids, carbohydrate, and protein. Clin Pharmacol Ther. 1979 Oct;26(4):493–501. [PubMed]
  • Aronow WS, Tobis J, Hughes D, Siegel J, Easthope J. Comparison of trimazosin and methyldopa in hypertension. Clin Pharmacol Ther. 1977 Oct;22(4):425–429. [PubMed]
  • Aronow WS, Greenfield RS, Alimadadian H, Danahy DT. Effect of the vasodilator trimazosin versus placebo on exercise performance in chronic left ventricular failure. Am J Cardiol. 1977 Nov;40(5):789–793. [PubMed]
  • Awan NA, Hermanovich J, Whitcomb C, Skinner P, Mason DT. Cardiocirculatory effects of afterload reduction with oral trimazosin in severe chronic congestive heart failure. Am J Cardiol. 1979 Jul;44(1):126–131. [PubMed]
  • De Gula D, Mendlowitz M, Russo C, Vlachakis ND, Antram S. The effect of trimazosin in essential hypertension. Curr Ther Res Clin Exp. 1973 Jul;15(7):339–348. [PubMed]
  • Falase AO, Salako LA, Aminu JM. Lack of effect of low doses of prazosin in hypertensive Nigerians. Curr Ther Res Clin Exp. 1976 Jun;19(6):603–611. [PubMed]
  • Franciosa JA, Cohn JN. Hemodynamic effects of trimazosin in patients with left ventricular failure. Clin Pharmacol Ther. 1978 Jan;23(1):11–18. [PubMed]
  • Fraser HS, Mucklow JC, Bulpitt CJ, Khan C, Mould G, Dollery CT. Environmental effects on antipyrine half-life in man. Clin Pharmacol Ther. 1977 Nov;22(5 Pt 2):799–808. [PubMed]
  • Hietanen E. Modification of hepatic drug metabolizing enzyme activities and their induction by dietary protein. Gen Pharmacol. 1980;11(5):443–450. [PubMed]
  • Houston JB. Drug metabolite kinetics. Pharmacol Ther. 1981;15(3):521–552. [PubMed]
  • Hughes MA, Meredith PA, Elliott HL. The determination of trimazosin and its metabolite CP23445 in whole blood by high performance liquid chromatography using fluorescence detection. J Pharmacol Methods. 1984 Aug;12(1):29–34. [PubMed]
  • Humphreys GS, Delvin DG. Ineffectiveness of propranolol in hypertensive Jamaicans. Br Med J. 1968 Jun 8;2(5605):601–603. [PMC free article] [PubMed]
  • Kalow W. Ethnic differences in drug metabolism. Clin Pharmacokinet. 1982 Sep-Oct;7(5):373–400. [PubMed]
  • Kappas A, Alvares AP, Anderson KE, Pantuck EJ, Pantuck CB, Chang R, Conney AH. Effect of charcoal-broiled beef on antipyrine and theophylline metabolism. Clin Pharmacol Ther. 1978 Apr;23(4):445–450. [PubMed]
  • Kappas A, Anderson KE, Conney AH, Alvares AP. Influence of dietary protein and carbohydrate on antipyrine and theophylline metabolism in man. Clin Pharmacol Ther. 1976 Dec;20(6):643–653. [PubMed]
  • Mbanefo C, Bababunmi EA, Mahgoub A, Sloan TP, Idle JR, Smith RL. A study of the debrisoquine hydroxylation polymorphism in a Nigerian population. Xenobiotica. 1980 Nov;10(11):811–818. [PubMed]
  • Meredith PA, Kelman AW, Elliott HL, Reid JL. Pharmacokinetic and pharmacodynamic modelling of trimazosin and its major metabolite. J Pharmacokinet Biopharm. 1983 Aug;11(4):323–335. [PubMed]
  • Reid JL, Meredith PA, Elliott HL. Pharmacokinetics and pharmacodynamics of trimazosin in man. Am Heart J. 1983 Nov;106(5 Pt 2):1222–1228. [PubMed]
  • Salako LA, Falase AO, Aderounmu AF. Placebo-controlled, double-blind clinical trial of alprenolol in African hypertensive patients. Curr Med Res Opin. 1979;6(5):358–363. [PubMed]
  • Scott JG. THE EYE OF THE WEST AFRICAN NEGRO. Br J Ophthalmol. 1945 Jan;29(1):12–19. [PMC free article] [PubMed]
  • Seedat YK, Reddy J. Propranolol in the South African non-white hypertensive patient. S Afr Med J. 1971 Mar 13;45(11):284–285. [PubMed]
  • Singleton W, Saxton CA, Hernandez J, Prichard BN. Postjunctional selectivity of alpha-blockade with prazosin, trimazosin, and UK-33,274 in man. J Cardiovasc Pharmacol. 1982;4 (Suppl 1):S145–S151. [PubMed]
  • Spector R, Choudhury AK, Chiang CK, Goldberg MJ, Ghoneim MM. Diphenhydramine in Orientals and Caucasians. Clin Pharmacol Ther. 1980 Aug;28(2):229–234. [PubMed]
  • Sumner DJ, Elliott HL, Reid JL. Analysis of the pressor dose response. Clin Pharmacol Ther. 1982 Oct;32(4):450–458. [PubMed]
  • Vlachakis ND, Mendlowitz M, De Guzman de Guzman D. Treatment of essential hypertension with trimazosin, a new vasodilator agent. Curr Ther Res Clin Exp. 1975 Jun;17(6):564–569. [PubMed]
  • Weber MA, Brewer DD, Drayer JI, Aronow WS, Lipson JL, Ricci BA. A vasodilator that avoids renin stimulation and fluid retention: antihypertensive treatment with trimazosin. Clin Pharmacol Ther. 1982 May;31(5):572–578. [PubMed]
  • Weber KT, Kinasewitz GT, West JS, Janicki JS, Reichek N, Fishman AP. Long-term vasodilator therapy with trimazosin in chronic cardiac failure. N Engl J Med. 1980 Jul 31;303(5):242–250. [PubMed]
  • Woolhouse NM, Andoh B, Mahgoub A, Sloan TP, Idle JR, Smith RL. Debrisoquin hydroxylation polymorphism among Ghanaians and Caucasians. Clin Pharmacol Ther. 1979 Nov;26(5):584–591. [PubMed]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

Formats:

Related citations in PubMed

See reviews...See all...

Links

  • Compound
    Compound
    PubChem Compound links
  • MedGen
    MedGen
    Related information in MedGen
  • PubMed
    PubMed
    PubMed citations for these articles
  • Substance
    Substance
    PubChem Substance links

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...